iRadimed CFO Receives 5,796 Shares, Sells Portion at $58.24 in Planned Transaction

iRadimed CFO John Glenn reported significant insider transactions on June 20, 2025.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

iRadimed CFO John Glenn reported significant insider transactions on June 20, 2025. The transactions involved:

Acquisition of 5,796 shares through the vesting of Restricted Stock Units (RSUs)
Disposition of 1,412 shares at $58.24 per share through share withholding for tax purposes
Net beneficial ownership change to 13,151 shares held directly

The RSUs were originally granted on June 20, 2022, under iRadimed's 2014 Equity Incentive Plan, vesting in four equal annual installments starting June 20, 2023. This transaction represents the third vesting installment. The Form 4 was filed within the required reporting timeframe, demonstrating compliance with SEC disclosure requirements.

Insider Trade Summary

5,796 shares exercised/converted

Exercise 3 txns

Insider GLENN JOHN

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	5,796	$0.00	$0.00
Exercise	Common Stock	5,796	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,412	$58.24	$82K

Holdings After Transaction: Restricted Stock Units — 5,796 contracts (Direct); Common Stock — 13,151 shares (Direct)

Footnotes (2)

F1. Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.
F2. On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRMD shares did CFO John Glenn receive from RSU vesting on June 20, 2025?

CFO John Glenn received 5,796 shares of IRMD common stock upon the vesting of restricted stock units (RSUs) on June 20, 2025.

How many IRMD shares did CFO John Glenn sell or dispose of on June 20, 2025?

John Glenn disposed of 1,412 shares of IRMD common stock at a price of $58.24 per share on June 20, 2025, likely for tax withholding purposes (indicated by transaction code 'F').

What is the vesting schedule for IRMD CFO John Glenn's RSU grant from 2022?

The RSUs granted to John Glenn on June 20, 2022, under Iradimed Corporation's 2014 Equity Incentive Plan vest in four equal annual installments beginning on June 20, 2023.

How many IRMD shares does CFO John Glenn own after the June 20, 2025 transactions?

Following the reported transactions on June 20, 2025, John Glenn directly owns 13,151 shares of IRMD common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2025 - 08:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GLENN JOHN

(Last)

(First)

(Middle)

C/O IRADIMED CORPORATION

1025 WILLA SPRINGS DR.

(Street)

WINTER SPRINGS

32708

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2025		M		5,796⁽¹⁾	A	⁽¹⁾	14,563	D
Common Stock	06/20/2025		F		1,412	D	$58.24	13,151	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/20/2025		M			5,796	⁽²⁾	⁽²⁾	Common Stock	5,796	$0	5,796	D

Explanation of Responses:

1. Represents shares of common stock that the Reporting Peron received upon the vesting of restricted stock units ("RSUs") on a one-for-one basis.

2. On June 20, 2022, the Reporting Person received RSUs under Iradimed Corporation's 2014 Equity Incentive Plan. The RSUs vest in four equal annual installments beginning on June 20, 2023. Upon vesting, the Reporting Person will receive a number of shares of common stock equal to the number of RSUs that have vested.

	/s/ John Glenn	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR